ClinicalTrials.gg
Not yet recruitingNCT07945340BRIGHTUpdated Nov 18, 2026

Effect of a Nicotinamide Riboside-Based Dietary Supplement on Retinal Function in Glaucoma (BRIGHT)

An interventional study of iNAD CONTROL and Placebo in Glaucoma, sponsored by Fondazione G.B. Bietti, IRCCS. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Fondazione G.B. Bietti, IRCCS · Not applicable, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn whether a daily dietary supplement called iNAD CONTROL can improve the function of the retinal ganglion cells (the nerve cells of the retina that carry visual information to the brain) in adults with open-angle glaucoma who are already being treated with eye-pressure-lowering therapy. iNAD CONTROL contains nicotinamide riboside (a form of vitamin B3), acetyl-L-carnitine, forskolin and hesperidin, which may support the energy metabolism of these nerve cells and protect them from damage.

The main question it aims to answer is:

- Does taking iNAD CONTROL for 12 weeks improve retinal ganglion cell function, measured with an electroretinogram (ERG, a test that records the electrical response of the retina to light), compared with a placebo (a look-alike tablet with no active ingredients)?

Researchers will also look at whether iNAD CONTROL changes the visual field, the thickness of the retinal nerve fiber layers measured with optical coherence tomography (OCT), visual acuity and eye pressure.

Researchers will compare iNAD CONTROL with placebo. Each participant will receive both: iNAD CONTROL for 12 weeks and placebo for 12 weeks, in a random order. Neither the participants nor the study doctors will know which product is being taken in each period.

Participants will:

  • Take 1 tablet a day for 24 weeks in total (12 weeks of iNAD CONTROL and 12 weeks of placebo)
  • Continue their usual glaucoma eye drops without changes
  • Attend 5 clinic visits over 6 months (at the start and at weeks 6, 12, 18 and 24)
  • At each visit, undergo non-invasive eye tests: visual acuity, eye pressure, visual field tests, ERG and OCT, plus blood pressure and body weight measurement
Read the detailed description

BACKGROUND Glaucoma is characterized by progressive dysfunction and loss of retinal ganglion cells (RGCs) and their axons. Oxidative stress and mitochondrial dysfunction are increasingly recognized as key mechanisms underlying RGC degeneration. Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor for mitochondrial ATP production and for NAD+-dependent enzymes that regulate cellular stress responses and survival. Patients with primary open-angle glaucoma have been shown to have reduced circulating levels of nicotinamide, a major NAD+ precursor, and preclinical studies have shown that raising retinal NAD+ levels protects RGCs and preserves retinal function in experimental glaucoma. Objective electrophysiological measures of inner retinal function, in particular the photopic negative response (PhNR) of the full-field electroretinogram (ERG), can detect short-term changes in RGC-related function and are suitable for interventional studies in which structural or perimetric changes are expected to be modest over a period of months.

RATIONALE This study evaluates RGC function in response to oral supplementation with nicotinamide riboside and acetyl-L-carnitine, compounds that support energy metabolism (direct neuroprotection), combined with forskolin and hesperidin, natural antioxidants that may support IOP-lowering therapy (indirect neuroprotection). Nicotinamide riboside and acetyl-L-carnitine together support the synthesis of acetyl-coenzyme A, and therefore of ATP and acetylcholine, even under the conditions of impaired glycolysis observed in glaucoma. Forskolin and hesperidin may help counteract sudden, transient increases in IOP despite hypotensive therapy. The combination is administered as the dietary supplement iNAD CONTROL.

STUDY DESIGN

Interventional, national, multicentre, prospective, double-masked, randomized, placebo-controlled 2x2 cross-over trial. Sixty adults with treated open-angle glaucoma (mean deviation between -3.0 and -12.0 dB) and stable IOP below 18 mmHg will be enrolled and randomized 1:1 to one of two treatment sequences:

  • Sequence A: iNAD CONTROL for 12 weeks (Period 1), followed by placebo for 12 weeks (Period 2)
  • Sequence B: placebo for 12 weeks (Period 1), followed by iNAD CONTROL for 12 weeks (Period 2) No wash-out period is included, as the supplement is expected to exert reversible biological effects without prolonged carry-over after discontinuation; carry-over and period effects will be assessed statistically.

INTERVENTION iNAD CONTROL, 1 tablet per day orally for 12 weeks. Each tablet contains acetyl-L-carnitine hydrochloride 500 mg, nicotinamide riboside chloride 300 mg, Coleus forskohlii dry root extract titrated at 20% forskolin 75 mg (15 mg forskolin) and micronized hesperidin 50 mg.

Placebo: a food product free of functional ingredients, matched to the study product in appearance and organoleptic characteristics, 1 tablet per day orally for 12 weeks.

Standard glaucoma treatment continues unchanged. Other systemic or topical agents with potential neuroprotective effects (e.g., citicoline) are prohibited during the study.

RANDOMIZATION AND MASKING The randomization list is generated by an independent statistician using a computer-generated schedule with permuted blocks of variable size. Randomization is centralized through the electronic study database and occurs only after eligibility is confirmed at the baseline visit. Participants, investigators, outcome assessors, study coordinators, data managers and statisticians involved in the primary analysis remain masked to treatment allocation. Study products are packaged and labelled identically.

STUDY VISITS AND PROCEDURES Each participant attends 5 visits over 24 weeks: Week 0 (baseline/randomization), Week 6, Week 12 (end of Period 1 and cross-over), Week 18 and Week 24 (end of Period 2/end of study). At every visit the following are performed: best-corrected visual acuity (ETDRS letters or logMAR), slit-lamp biomicroscopy, Goldmann applanation tonometry, blood pressure, body weight, standard automated perimetry, photopic ERG, SD-OCT, adverse event recording, concomitant medication review and pill count for adherence.

  • Perimetry: Humphrey Field Analyzer, 24-2 SITA Standard repeated twice per eye (the mean of the two reliable tests is used) and 10-2 SITA Standard once per eye, in the sequence 24-2, 24-2, 10-2.
  • ERG: handheld RETeval device (LKC Technologies) with skin electrodes after pharmacological pupil dilation and standardized photopic adaptation; photopic full-field ERG with a red flash on a blue background (CD LONG protocol), with harmonized settings across centres. Waveforms are processed centrally by masked assessors. The PhNR peak-to-trough amplitude (PhNRPT, distance in microvolts from the b-wave peak to the trough of the PhNR) is calculated as the mean of 3 consecutive recordings. The W-ratio is calculated as (b-wave amplitude - PhNR trough) / (b-wave amplitude - a-wave amplitude).
  • OCT: circumpapillary RNFL and ganglion cell complex (GCC) thickness (Spectralis SD-OCT, Heidelberg Engineering, or Cirrus HD-OCT, Carl Zeiss Meditec).

One eye per participant is designated as the study eye; if both eyes are eligible, the eye with the better quality visual field at screening is selected.

STATISTICAL ANALYSIS The sample size was informed by a similar cross-over trial of nicotinamide in glaucoma (Hui et al., 2020). Enrolling 60 participants, allowing for approximately 20% attrition or unreliable ERG/visual field measurements, is expected to provide at least 48 evaluable participants and 80% power to detect a clinically meaningful difference in PhNRPT between treatment periods (two-sided alpha 0.05).

The primary analysis set includes participants with outcome data after both treatment periods; a per-protocol analysis includes adherent participants without major protocol deviations. The difference between iNAD CONTROL and placebo in change from baseline in PhNRPT after each 12-week period will be assessed with linear mixed models adjusting for baseline value, period and centre. Prespecified tests for carry-over and period effects will be performed; if clinically important carry-over is detected, a sensitivity analysis using first-period data only will be performed. Missing data will be handled with mixed models under a missing-at-random assumption, with multiple imputation and complete-case sensitivity analyses. Secondary endpoints will be analysed within the same cross-over framework, with multiplicity addressed by a hierarchical approach or emphasis on effect sizes and confidence intervals. An exploratory analysis will assess the effect across disease stages, including both eyes where eligible, with adjustment for inter-eye correlation.

FUNDING The study is sponsored by IRCCS Fondazione G.B. Bietti and partially funded by an unrestricted grant from OFFHEALTH, which also supplies iNAD CONTROL and placebo free of charge and has no role in study design, data collection, analysis, interpretation or publication.

02

Conditions studied

  • Glaucoma

Browse trials for

Keywords

  • Retinal ganglion cells
  • PhNR
  • Electroretinography
  • Neuroprotection
  • Nicotinamide
03

In context

Glaucoma

1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.

This study's planned enrollment of 60 is close to the median of 61 across 965 interventional studies indexed under Glaucoma.

Browse Glaucoma studies →

Lead sponsor

Fondazione G.B. Bietti, IRCCS is the lead sponsor of 21 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Freely given written obtained prior to any study procedure
  • Capacity to understand and willingness to follow study instructions, and likely to complete all required visits and procedures
  • Diagnosis of open-angle glaucoma under IOP-lowering treatment
  • Visual field mean deviation (MD) between -3.0 and -12.0 dB
  • Best-corrected visual acuity of 8/10 (0.1 logMAR) or better
  • Spherical refraction between +3 and -4 diopters and astigmatism within ±3 diopters
  • IOP below 18 mmHg at the 2 previous visits and at the screening visit
  • Stable IOP-lowering regimen planned for the next 6 months, as judged by the investigator
  • Reliable Humphrey 24-2 visual field at screening/baseline (fixation losses and false negatives below 15%, false positives below 10%)
  • Reproducible glaucomatous visual field defect, defined as Glaucoma Hemifield Test outside normal limits and a cluster of 3 or more locations on the pattern deviation plot, 2 of which are depressed at P\<5% and 1 at P\<1%, on at least 2 consecutive reliable fields, with at least 1 common location in the cluster depressed at P\<5% in both fields (30-2 or 24-2 tests may be used, considering only the 24-2 locations)
  • At least 3 visual field examinations performed in the 3 years prior to enrollment, to minimize learning effects
  • Women of must agree to use an appropriate method and have a negative urine pregnancy test on the first day of dosing

Only one eye per participant is designated as the study eye. If both eyes are eligible, the eye with the better quality visual field at screening (lower fixation losses and false-positive rates) is selected. Ocular inclusion criteria (MD, IOP, visual acuity, refraction, astigmatism) apply to the study eye only; the fellow eye must not meet any exclusion criterion that could confound interpretation of results.

Exclusion criteria

Exclusion Criteria:

  • Intraocular surgery within the previous 6 months, or surgery planned during the study
  • Coexisting retinal or optic nerve disease (e.g., non-glaucomatous optic neuropathies of ischemic, inflammatory or compressive origin), moderate-to-severe diabetic retinopathy, advanced macular degeneration, or advanced cataract likely to confound ERG, visual field or OCT interpretation
  • Use of any other systemic or topical agent with potential neuroprotective effects (e.g., citicoline) within the previous month or planned during the study
  • Changes in IOP-lowering therapy within the previous 3 months
  • Pregnancy or breastfeeding
  • Known allergy to nicotinamide riboside, acetyl-L-carnitine, forskolin, hesperidin or any
  • hepatic disease or active gastrointestinal ulcer disease
  • Severe renal impairment (e.g., below 30 mL/min/1.73 m²) or other condition judged by the investigator to increase risk
  • History of cancer within the past 5 years
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Sequence A: iNAD CONTROL then Placebo

    Participants take iNAD CONTROL, 1 tablet orally once daily, for 12 weeks (Period 1), then cross over at Week 12 without a wash-out period to matching placebo, 1 tablet orally once daily, for 12 weeks (Period 2). Usual IOP-lowering glaucoma therapy continues unchanged throughout.

    Dietary Supplement: iNAD CONTROL · Dietary Supplement: Placebo

  • Experimental
    Sequence B: Placebo then iNAD CONTROL

    Participants take matching placebo, 1 tablet orally once daily, for 12 weeks (Period 1), then cross over at Week 12 without a wash-out period to iNAD CONTROL, 1 tablet orally once daily, for 12 weeks (Period 2). Usual IOP-lowering glaucoma therapy continues unchanged throughout.

    Dietary Supplement: iNAD CONTROL · Dietary Supplement: Placebo

Interventions

  • Dietary supplementiNAD CONTROL

    Oral dietary supplement, 1 tri-layer tablet once daily for 12 weeks. Each tablet contains acetyl-L-carnitine hydrochloride 500 mg, nicotinamide riboside chloride 300 mg, Coleus forskohlii dry root extract titrated at 20% forskolin 75 mg (equivalent to 15 mg forskolin) and micronized hesperidin 50 mg. Gluten-free and lactose-free. Supplied free of charge by OFFHEALTH.

  • Dietary supplementPlacebo

    Oral placebo tablet, 1 tablet once daily for 12 weeks. A food product free of functional ingredients, containing only excipients, matched to iNAD CONTROL in appearance and organoleptic characteristics and packaged identically to maintain masking.

06

What researchers measure

Primary outcomes

  1. Change in PhNR Peak-to-Trough Amplitude (PhNRPT)

    Change from the start to the end of each 12-week treatment period (iNAD CONTROL vs placebo) in the photopic negative response peak-to-trough amplitude (PhNRPT), defined as the distance in microvolts from the peak of the b-wave to the trough of the subsequent photopic negative response (PhNR), recorded in the study eye with photopic full-field ERG (RETeval, red flash on blue background, CD LONG protocol) after pupil dilation. The value at each timepoint is the mean of 3 consecutive ERG recordings, processed centrally by masked assessors. Higher values indicate better retinal ganglion cell function.

    Time frame: Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)

Secondary outcomes

  1. Change in ERG b-Wave Amplitude

    Change from the start to the end of each 12-week treatment period (iNAD CONTROL vs placebo) in photopic ERG b-wave amplitude (microvolts) in the study eye, recorded with RETeval (red flash on blue background, CD LONG protocol) and processed centrally by masked assessors.

    Time frame: Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)

  2. Change in ERG b-Wave Implicit Time

    Change from the start to the end of each 12-week treatment period (iNAD CONTROL vs placebo) in photopic ERG b-wave latency (implicit time, milliseconds) in the study eye.

    Time frame: Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)

  3. Change in Photopic Electroretinogram (ERG) W-Ratio

    The reported outcome is the within-period change in the dimensionless photopic ERG W-ratio in the study eye, calculated as the end-of-period W-ratio minus the start-of-period W-ratio for each 12-week treatment period. At each assessment, a single W-ratio is calculated from the photopic ERG waveform as (b-wave amplitude - PhNR trough) / (b-wave amplitude - a-wave amplitude), where PhNR is the photopic negative response.

    Time frame: Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)

  4. Change in Circumpapillary Retinal Nerve Fiber Layer (RNFL) Thickness and Ganglion Cell Complex (GCC) Thickness

    Change from the start to the end of each 12-week treatment period (iNAD CONTROL vs placebo) in global circumpapillary RNFL thickness (micrometers) and macular ganglion cell complex thickness (micrometers) in the study eye, measured with spectral-domain OCT.

    Time frame: Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)

  5. Change in Best-Corrected Visual Acuity (BCVA)

    Change from the start to the end of each 12-week treatment period (iNAD CONTROL vs placebo) in best-corrected visual acuity in the study eye, measured with ETDRS charts and expressed as logMAR. Lower logMAR values indicate better vision.

    Time frame: Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)

  6. Change in Intraocular Pressure (IOP)

    Change from the start to the end of each 12-week treatment period (iNAD CONTROL vs placebo) in intraocular pressure (mmHg) in the study eye, measured with Goldmann applanation tonometry.

    Time frame: Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)

  7. Change in Mean Arterial Pressure (MAP)

    Change from the start to the end of each 12-week treatment period (iNAD CONTROL vs placebo) in mean arterial pressure (mmHg), calculated from systolic and diastolic blood pressure.

    Time frame: Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)

  8. Proportion of Participants With a Change of at Least 1 dB in Visual Field Mean Deviation and Pattern Standard Deviation

    Percentage of participants whose visual field mean deviation and pattern standard deviation in the study eye improves by at least 1 dB, and percentage whose mean deviation and pattern standard deviation worsens by at least 1 dB, from the start to the end of each 12-week treatment period (iNAD CONTROL vs placebo).

    Time frame: Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)

  9. Change in 24-2 Visual Field Mean Deviation (MD)

    Change in visual field mean deviation (dB) in the study eye, calculated as the end-of-period value minus the start-of-period value for each 12-week treatment period. Mean deviation is measured with Humphrey 24-2 SITA Standard and averaged across two reliable tests per visit.

    Time frame: Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)

  10. Change in 24-2 Visual Field Pattern Standard Deviation (PSD)

    Change in visual field pattern standard deviation (dB) in the study eye, calculated as the end-of-period value minus the start-of-period value for each 12-week treatment period. Pattern standard deviation is measured with Humphrey 24-2 SITA Standard and averaged across two reliable tests per visit.

    Time frame: Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)

  11. Change in 24-2 Visual Field Mean Light Sensitivity (MLS)

    Change in visual field mean light sensitivity (dB) in the study eye, calculated as the end-of-period value minus the start-of-period value for each 12-week treatment period. Mean light sensitivity is obtained from Humphrey 24-2 SITA Standard testing and averaged across two reliable tests per visit.

    Time frame: Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)

  12. Change in 10-2 Visual Field Mean Deviation (MD)

    Change in visual field mean deviation (dB) in the study eye, calculated as the end-of-period value minus the start-of-period value for each 12-week treatment period. Mean deviation is measured with Humphrey 10-2 SITA Standard using one test per visit.

    Time frame: Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)

  13. Change in 10-2 Visual Field Pattern Standard Deviation (PSD)

    Change in visual field pattern standard deviation (dB) in the study eye, calculated as the end-of-period value minus the start-of-period value for each 12-week treatment period. Pattern standard deviation is measured with Humphrey 10-2 SITA Standard using one test per visit.

    Time frame: Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)

  14. Change in 10-2 Visual Field Mean Light Sensitivity (MLS)

    Change in visual field mean light sensitivity (dB) in the study eye, calculated as the end-of-period value minus the start-of-period value for each 12-week treatment period. Mean light sensitivity is obtained from Humphrey 10-2 SITA Standard testing using one test per visit.

    Time frame: Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared. Data ownership lies with the Sponsor (IRCCS Fondazione G.B. Bietti), and in accordance with the protocol and the EU General Data Protection Regulation (GDPR), study results will be disseminated only in anonymous and aggregated form through scientific publications.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Apr 2028, 18 months later.

Of 230 non-industry interventional studies with no phase under Glaucoma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 18 months is below that.

Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 12 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2026
First posted
Nov 18, 2026
StartEst.
Oct 19, 2026
Primary completionEst.
Apr 2028
CompletionEst.
Oct 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945340
Lead sponsor
Fondazione G.B. Bietti, IRCCS
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Oct 19, 2026 (estimated)
Primary completion
Apr 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Francesco Oddone
Contact
francesco.oddone@fondazionebietti.it
0684009442
Carmela Carnevale
Contact
0684009442

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion